Fortress Biotech, Inc. (FBIO) stock
FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
$1.88−0.11 (-5.53%)
Close on Nov 13, 2026Market cap $69.14MP/E –Yield –
Earnings
Fortress Biotech's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 30, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$19.20M
+9.1% on a year earlier
Adjusted EPS, Q3 FY2026
-$0.23
$0.11 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Fortress Biotech's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 30, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 13, 2026before the open | $19.20M | +9.1% | -$0.23 | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026after the close | $18.70M | +14.0% | -$0.08 | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026after the close | $16.00M | +22.1% | $2.82 | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 31, 2026after the close | – | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 14, 2025before the open | $17.60M | +20.5% | $0.11 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025after the close | $16.40M | +10.1% | $0.45 | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 15, 2025after the close | $13.10M | +0.8% | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 31, 2025after the close | – | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024after the close | $14.60M | -58.0% | -$0.76 | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024after the close | $14.90M | -14.4% | -$0.73 | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 15, 2024after the close | $13.00M | +4.8% | -$1.03 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 28, 2024after the close | – | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023after the close | $34.80M | +110.9% | -$0.94 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023after the close | $17.40M | -7.9% | -$0.24 | -$0.07 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023after the close | $12.40M | -48.1% | -$0.21 | -$0.06 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 30, 2023after the close | – | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022after the close | $16.50M | -21.8% | -$0.25 | -$0.08 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022after the close | $18.90M | – | -$0.24 | -$0.10 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022after the close | $23.90M | – | -$0.18 | -$0.07 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 28, 2022before the open | – | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021after the close | $21.10M | – | -$0.26 | $0.54 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 16, 2021after the close | – | – | – | – | Release |
| Q1 FY2021ended Mar 31, 2021 | May 17, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 31, 2021after the close | – | – | – | – | Release |
| Q3 FY2020ended Sep 30, 2020 | Nov 9, 2020after the close | – | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Fortress Biotech has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Fortress Biotech puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Fortress Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
- News
- News
- Results
- News
- Results
- Results
- Results
- Results
- Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private PlacementsNews
See a number that looks wrong?